Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
eloxatin · 1 trial · 1 indication
Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) as a 20 percent (%) increase in the sum of the longest diameter of target lesions, or a measureable increase in a non-target lesion, or the appearance of new lesions.
Progression-free survival was defined as the time from the date of informed consent until the date when the participant had progression of disease or died from disease progression. Participants who received surgical treatment after treatment ended were censored at the time of surgery. Participants who left the study for reasons other than progression of the disease were censored on the date on which they received a later antitumor therapy (with the same or different drugs, radiotherapy, or surgery).
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bevacizumab [Avastin] | DRUG | Intravenous repeating dose |
| eloxatin | DRUG | Intravenous repeating dose |
| capecitabine [Xeloda] | DRUG | Oral repeating dose |
| erlotinib [Tarceva] | DRUG | Oral repeating dose |
Inclusion Criteria: * adult patients, \>=18 years of age; * adenocarcinoma of colon or rectum, with metastatic disease; * \>=1 measurable lesion. Exclusion Criteria: * previous treatment with Avastin or Tarceva; * previous systemic treatment for advanced or metastatic disease; * adjuvant treatmen...
Top 20 of 77 competitors
Eloxatin is used for colorectal cancer. It is a small molecule oncology drug being developed by Roche Holding AG (RHHBY). Eloxatin is currently in Phase 2 clinical development for this indication.
Eloxatin is a small molecule used in oncology. Its specific molecular target is not disclosed in the available information. The drug is being studied for the treatment of colorectal cancer.
Eloxatin is developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on Eloxatin for the treatment of colorectal cancer.
Eloxatin is in Phase 2 clinical development. It is an investigational drug for colorectal cancer and has not been approved by regulatory authorities. One Phase 2 trial has been completed.
Eloxatin has one completed clinical trial, NCT01135498, titled 'A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.' This Phase 2 study enrolled 90 participants in Spain.
Eloxatin is the brand name for oxaliplatin. The drug is a platinum-based chemotherapy agent used in the treatment of colorectal cancer. It is being studied in combination with other agents for metastatic colorectal cancer.